Journal Article Review Epublish 7 citations
PubMed: 39669992 DOI: 10.3389/fmed.2024.1512916
Unraveling the cGAS/STING signaling mechanism: impact on glycerolipid metabolism and diseases.
Front Med (Lausanne) 11:1512916
Authors: Jie Su, Fuyu Cheng, Wei Yuan
Affiliations
- Department of Cardiology, Hospital of Jiangsu University, Zhenjiang, China. The British Heart Foundation Centre of Excellence, St Thomas' Hospital, School of Cardiovascular and Metabolic Medicine and Sciences, King's College London, The Rayne Institute, London, United Kingdom.
- Department of Cardiology, Hospital of Jiangsu University, Zhenjiang, China. School of Engineering and Material Sciences, Digital Environment Research Institute, Queen Mary University of London, London, United Kingdom.
- Department of Cardiology, Hospital of Jiangsu University, Zhenjiang, China.
Abstract
The cyclic GMP-AMP synthase (cGAS) and its downstream effector, the stimulator of interferon genes (STING), are crucial components of the innate immune response, traditionally recognized for their role in detecting cytosolic DNA from pathogens and damaged host cells. However, recent research indicates that the cGAS-STING pathway also significantly impacts metabolic processes, particularly glycerolipid metabolism. Glycerolipids are essential for energy storage and cellular membrane integrity, and their dysregulation is linked to metabolic disorders such as obesity, insulin resistance, and non-alcoholic fatty liver disease (NAFLD). Both cGAS and STING are expressed in various metabolic tissues, suggesting a potential role in lipid homeostasis. Chronic activation of the cGAS-STING pathway may promote inflammatory states that exacerbate insulin resistance and lipid accumulation, forming a feedback loop of metabolic dysfunction. This review explores the emerging relationship between cGAS/STING signaling and glycerolipid metabolism, discussing the mechanisms through which this pathway influences lipid regulation and the potential for therapeutic interventions. By integrating insights from immunology and metabolism, we aim to provide a comprehensive understanding of how the cGAS-STING axis may serve as a novel target for addressing metabolic disorders and enhancing metabolic health outcomes.
MeSH
Insulin Resistance, Insulin, Non-Alcoholic Fatty Liver Disease, Cardiovascular Diseases, Immunity, Cgas-Sting Signaling Pathway